HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 51, 39033-39040, December 22, 2006

This Article Abstract Full Text (PDF) All Versions of this Article: 281/51/39033    most recent M605097200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jin, Y. Articles by Gallagher, P. J. Search for Related Content PubMed PubMed Citation Articles by Jin, Y. Articles by Gallagher, P. J. Social Bookmarking                      What's this?

Control of Death-associated Protein Kinase (DAPK) Activity by Phosphorylation and Proteasomal Degradation^*

Yijun Jin, Emily K. Blue, and Patricia J. Gallagher¹

From the Department of Molecular and Cellular Physiology, Louisiana State University Health Science Center, Shreveport, Louisiana 71103 and the Department of Cellular and Integrated Physiology, Indiana University School of Medicine, Indianapolis, Indiana 46202

Received for publication, May 30, 2006 , and in revised form, September 11, 2006.

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Activation of death-associated protein kinase (DAPK) occurs via dephosphorylation of Ser-308 and subsequent association of calcium/calmodulin. In this study, we confirmed the existence of the alternatively spliced human DAPK-, and we examined the levels of DAPK autophosphorylation and DAPK catalytic activity in response to tumor necrosis factor or ceramide. It was found that DAPK is rapidly dephosphorylated in response to tumor necrosis factor or ceramide and then subsequently degraded via proteasome activity. Dephosphorylation and activation of DAPK are shown to temporally precede its subsequent degradation. This results in an initial increase in kinase activity followed by a decrease in DAPK expression and activity. The decline in DAPK expression is paralleled with increased caspase activity and cell apoptosis. These results suggest that the apoptosis regulatory activities mediated by DAPK are controlled both by phosphorylation status and protein stability.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Apoptosis is a highly coordinated cellular process that serves to eliminate unwanted cells. Because of its fundamental role in maintaining the integrity of multicellular organisms, it is not surprising that apoptosis is tightly regulated by a multitude of signaling proteins, including death-associated protein kinase (DAPK)² (1). DAPK has been implicated in regulating apoptosis induced by a variety of stimuli, including tumor necrosis factor (TNF) and ceramide as well as oncogenes such as c-Myc and p53 (2–7). Depending on the particular cell type, the response to specific apoptosis inducers can vary, and DAPK can either promote (3–5, 8) or antagonize apoptosis (2, 7). Regardless of the apoptotic outcome, the effects of DAPK are dependent upon its catalytic activity as well as by its interaction with other proteins through its noncatalytic domains (2, 9–13).

The kinase domain of DAPK has a high homology to the kinase domain of smooth muscle myosin light chain kinase and as expected can also phosphorylate the regulatory light chain (RLC) of myosin II. Studies have confirmed that a conserved lysine residue within the catalytic site is important for ATP binding, and mutation of this lysine (K42W or K42A) abolishes the effect of DAPK on apoptosis (2, 9). The catalytic activity of DAPK is regulated by Ca²⁺/CaM and by autophosphorylation of Ser-308 within the Ca²⁺/CaM binding domain. Similar to myosin light chain kinase, phosphorylation of this site inhibits Ca²⁺/CaM binding and provides a mechanism that negatively regulates DAPK activity (14–16).

DAPK has been shown to interact with DIP1/MIB1 (DAPK-interacting protein-1/mind-bomb) primarily through the ankyrin repeats domain of DAPK (17, 18). DIP1/MIB1 is an E3 ligase, and among its multiple functions, it mediates the poly-ubiquitination and proteasomal degradation of DAPK (17) and the mono-ubiquitination of Delta ligand in the Notch signaling pathway (18). This finding raises the possibility that controlling DAPK stability may be a mechanism to regulate the protein levels of DAPK and hence its overall activity. Consistent with this proposal is a recent study demonstrating that HSP90 binds to and stabilizes DAPK, providing another pathway to regulate the activities of this complex kinase (19). Ubiquitination and subsequent proteasomal degradation are common mechanisms for controlling the level of proteins involved in regulating apoptosis, such as caspases and inhibitors of caspases. It has been reported that the expression of DAPK is lost in some types of cancer by promoter hypermethylation, although the significance of down-regulating DAPK expression in the transition of these normal cells to transformed cells is uncertain when the dual pro- and anti-apoptotic functions of this kinase are considered (20–27). In this study, we determined whether the expression level of DAPK is acutely altered during TNF- or ceramide-induced apoptosis and whether ubiquitination and proteasomal degradation are responsible for the change in DAPK protein levels.

One important aspect of DAPK functionality that has not been extensively pursued is the relationship between activation of DAPK and the stability of the protein in response to apoptotic stimuli (17). In this study, we examined the kinase activity of DAPK during TNF- or ceramide-induced apoptosis, and its relationship to DAPK Ser-308 phosphorylation and total DAPK protein levels. We found that DAPK activities, which are critical in determining the progression of TNF- or ceramide-induced apoptosis (3–5, 8), are modulated both by autophosphorylation of Ser-308 and by proteasomal degradation. These studies reveal that alterations in DAPK stability in addition to changes in its kinase activity occur in response to these stimuli. These alterations occur in a temporally distinct pattern during the progression of apoptosis, and it is likely that the balance of these activities ultimately determines the pro- or anti-apoptotic outcome. Thus, when phosphorylation of Ser-308 is low, survival predominates, and when proteasomal degradation is increased to deplete cellular levels of DAPK, apoptosis ensues.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Cells, Antibodies, and Reagents—HeLa cells are from the ATCC (Manassas, VA). HeLa cells expressing tetracycline-inducible mouse DAPK- or DAPK- were created and maintained in this laboratory as described previously (2). Antibodies to DAPK (clone DAPK-55) and DAPK phosphorylated on Ser-308 (clone DKPS308) were purchased from Sigma. Antibodies to poly(ADP-ribose) polymerase (PARP) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Human tumor necrosis factor- (TNF) and cycloheximide (CHX) were purchased from Calbiochem. The proteasome inhibitor, MG-132, and N-hexanoyl-D-sphingosine (C₆-ceramide) were from Sigma.

RT-PCR Detection of Human DAPK-—First Choice RACE-ready cDNA from human brain was purchased from Ambion. Total RNA from human coronary artery smooth muscle primary cells (Cell Applications, Inc.) was prepared using Trizol according to the manufacturer's instructions (Invitrogen), and cDNA synthesis was performed in a mixture containing 400 ng of total RNA, random primers, and reverse transcriptase (Invitrogen). For RT-PCR detection of DAPK- and DAPK- isoform mRNAs, a combination of a sense primer (SP) 5'-TTGCTGAAGGCATCCTCTGTG-3' (SP1), 5'-TCAGACCTGAACCTCCTCACTCG-3' (SP2), and an antisense primer (ASP) of 5'-ACAGAGAGGTAGCGTTTCCTTG-3' (ASP1) was used to generate fragments. The amplification was carried out in a 50-µl mixture containing 1 µl of cDNA, 1 mM each of the sense and antisense primers, 1 unit of Platinum Taq High Fidelity, 1x High Fidelity PCR Buffer, and 0.2 mM dNTPs (Invitrogen). The reaction conditions were as follows: initial denaturation at 94 °C for 2 min and 35–45 cycles of amplification (94 °C for 0.5 min, 55 °C for 0.5 min, and 68 °C for 0.75 min), followed by a final extension step of 10 min at 68 °C. The products were analyzed by agarose gel electrophoresis for size estimation, subcloned into pCR4-TOPO using the TOPO TA cloning kit (Invitrogen), and were sequenced to verify the insert. The nucleotide sequence for the PCR fragment confirming the alternatively spliced human DAPK- has been deposited in the GenBank^TM under accession number EF090258 [GenBank] .

Immunoprecipitation and in Vitro Kinase Assay—Endogenous human DAPK or overexpressed mouse mutant (S308A or S308D) DAPK was immunoprecipitated from HeLa cells and subjected to an in vitro kinase assay as described previously (2). The amount of phosphorylated RLC was quantified from Western blotting of phospho-RLC using an antibody specific for RLC phosphorylated on Ser-19, purchased from Cell Signaling Technology.

Alkaline Phosphatase Treatment and Calmodulin Overlay Assay—Immunoprecipitated DAPK was washed and incubated with 50 units of calf intestine alkaline phosphatase (AP, New England Biolabs) in a buffer containing 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl for 30 min at room temperature. For calmodulin overlay assay, immunoprecipitated DAPK was Western-blotted and incubated with biotinylated calmodulin (CaM, Sigma) in a buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM Ca²⁺ and 5% nonfat dry milk. Calmodulin was detected with streptavidin-conjugated horseradish peroxidase (The Jackson Laboratory).

Caspase Activity Assay—Caspase assays utilize specific caspase substrates Ac-IETD-pNA (caspase-8), Ac-DEVD-pNA (caspase-3), or Ac-LEHD-pNA (caspase-9) (7). For measurement of caspase activity in vivo, both adherent and floating cells were collected and lysed with CHAPS lysis buffer (0.1% CHAPS, 100 mM NaCl, 100 µM EDTA, 10 mM dithiothreitol, and 50 mM HEPES, pH 7.4). For every cell sample, nonspecific background was determined by adding the caspase inhibitors, acetyl-IETD-aldehyde (Ac-IETD-CHO; caspase-8), acetyl-DEVD-aldehyde (Ac-DEVD-CHO; caspase-3), or acetyl-LEHD-aldehyde (Ac-LEHD-CHO; caspase-9) as negative control.

Cell Death Assay—Quantification of apoptotic cell death was performed as described previously (2). Briefly, after 4 h of treatment with TNF (10 ng/ml) and CHX (10 µg/ml), cells were fixed and stained for LacZ expression. Apoptotic cells with membrane blebbing were identified morphologically and counted. The extent of apoptosis is defined as follows: (the number of blue apoptotic cells)/(the total number of blue cells).

Data Analysis—All experiments were independently performed at least three times. All statistic analysis and graphs were created using GraphPad Prism software (GraphPad Software, San Diego). Phospho-DAPK level is normalized to the level of total DAPK in Fig. 2C. Western blotting data were quantified by densitometry and are representative of at least three repeated experiments.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Dephosphorylation of Ser-308 in DAPK Enhances Kinase Activity—DAPK is phosphorylated on several residues, including an autophosphorylation site at Ser-308 (14). Mutation of Ser-308 to alanine increases the Ca²⁺/CaM-dependent kinase activity of DAPK (14). In this study, we investigated whether dephosphorylation of Ser-308 of the endogenous DAPK was capable of increasing DAPK activity. Initially, the basal level of human DAPK autophosphorylated at Ser-308 (phospho-DAPK) in HeLa cells was determined by immunoprecipitation utilizing an antibody specific for DAPK phosphorylated at Ser-308. The relative levels of phospho-DAPK and nonphosphorylated DAPK were detected and quantified following Western blotting of the immunoprecipitate and the immunoprecipitation supernatant (Fig. 1A). This analysis showed that the relative levels of immunoprecipitated phospho-DAPK and nonphosphorylated DAPK remaining in the post-immunoprecipitation supernatant are approximately equal, suggesting that about 50% of human DAPK is autophosphorylated on Ser-308 under basal conditions.

View larger version (30K): [in this window] [in a new window]   FIGURE 1. DAPK dephosphorylated at Ser-308 has increased kinase activity. A, Western blotting (WB) to detect immunoprecipitated (IP) phospho-DAPK and the level of unphosphorylated DAPK remaining in the supernatant following immuno-depletion of phospho-DAPK. Phosphorylated human DAPK (HuDAPK) from HeLa cells was immunoprecipitated with an antibody specific for DAPK phosphorylated at Ser-308; Western blotting was performed using a DAPK-specific antibody that detects both phospho-DAPK and unphosphorylated DAPK. B, Western blotting and CaM overlay of immunoprecipitated endogenous human DAPK treated with AP. The CaM overlay was carried out using biotinylated CaM (100 nM) in Tris buffer containing 10 mM Ca2+. C, endogenous human DAPK was immunoprecipitated from HeLa cells. Immunoprecipitates were treated with AP to dephosphorylate the DAPK or with vehicle as a control. The kinase activity of the immunoprecipitates was then determined using myosin II RLC as a substrate in either the presence or absence of 600 µM Ca2+. Western blots shown are representative of at least three independent analyses. Kinase assays were repeated at least three times.

DAPK Expression and Activity Decrease following Dephosphorylation during TNF- and Ceramide-induced Apoptosis—DAPK has an important kinase-dependent role in regulating TNF- or ceramide-induced apoptosis (3, 5, 9, 14). We thus examined levels of the endogenous human DAPK activity in HeLa cells treated with TNF (10 ng/ml) and CHX (10 µg/ml) or CHX alone (data not shown) for up to 6 h, or with C₆-ceramide (50 µM) for up to 32 h. Endogenous DAPK was immunoprecipitated, and its kinase activity was determined by an in vitro kinase assay with myosin II RLC as substrate. Phospho-RLC was detected with a specific antibody that detects phosphorylation of Ser-19 and quantified by densitometric scanning (Fig. 2A). Although the kinase assays were performed both in the presence or absence of Ca²⁺/CaM, only results from assays conducted in the presence of Ca²⁺/CaM are shown as both Ca²⁺/CaM-dependent and -independent kinase activities of DAPK had similar changes in the magnitude of the response to TNF. These results demonstrate that DAPK kinase activity increases between 15 and 30 min in response to TNF treatment, reaching 3-fold higher than the initial level by 60 min. After 60 min, DAPK activity drops dramatically, dipping below the initial level of kinase activity at 120 min and having only 50% of the initial kinase activity left after 6 h of TNF/CHX treatment. DAPK activities in HeLa cells treated with C₆-ceramide for up to 32 h have similar biphasic profiles, in which DAPK kinase activity gradually increases to greater than 2-fold of the basal level by 8 h and thereafter declines to basal level.

To determine the relationship between DAPK activity and DAPK autophosphorylation, protein levels of phospho-DAPK as well as total DAPK were analyzed by Western blotting (Fig. 2, B and C). Expression of phospho-DAPK begins to decline beginning between 15 and 30 min of TNF/CHX treatment or following 2 h of ceramide treatment. Total levels of DAPK also decrease, although this is not detectable until after 2 h of TNF/CHX treatment or after of 16 h of ceramide. Normalization of phospho-DAPK level to the total DAPK level revealed that TNF treatment induces a rapid and sustained dephosphorylation of DAPK at Ser-308. After 60 min of TNF/CHX treatment (Fig. 2, B and C), the level of phosphorylation is only 20% that of nontreated cells. Because it was determined that 50% of the total DAPK in nontreated cells is autophosphorylated (Fig. 1A), then by extrapolation, in the TNF/CHX cells only 10% of total DAPK will be autophosphorylated after 60 min. A similar decrease in phosphorylation of DAPK at Ser-308 is also detected after 8 h of C₆-ceramide treatment (Fig. 2, B and C). Together these data define the temporal succession of events that begin with dephosphorylation of Ser-308 to result in increased catalytic activity and the subsequent decline in activity, which results from the decrease in DAPK expression.

View larger version (35K): [in this window] [in a new window]   FIGURE 2. DAPK activity during TNF- or ceramide-induced apoptosis. A, kinase activity assay of immunoprecipitated total human DAPK from HeLa cells treated either with TNF (10 ng/ml)/cycloheximide (CHX, 10 µg/ml) or C6-ceramide (50 µM) for the indicated times, using myosin II RLC as substrate. B, Western blotting of total human DAPK (HuDAPK) and DAPK phosphorylated at Ser-308 in HeLa cells treated either with TNF (10 ng/ml)/CHX (10 µg/ml) or C6-ceramide (50 µM). C, graphs showing the relationship between the levels of human total DAPK, phospho-DAPK, and caspase-9 activity in HeLa cells treated with either TNF (10 ng/ml)/CHX (10 µg/ml) or ceramide (50 µM). The level of phosphorylated DAPK is normalized to the level of total DAPK at each time point. All experiments were repeated at least three times.

A Mutant, Unphosphorylatable DAPK (DAPK-S308A), Protects Cells from TNF- or Ceramide-induced Apoptosis—The above results suggest that in response to TNF or ceramide, DAPK is initially dephosphorylated and activated, perhaps to antagonize and attenuate the apoptotic signaling of TNF or ceramide. If this is true, then overexpression of a mutant DAPK lacking the auto-phosphorylation site (DAPK-S308A) should protect cells from TNF- or ceramide-induced apoptosis. To test this, we expressed mutant unphosphorylatable mouse DAPK-S308A and DAPK-S308D, a phosphomimetic mutant with a serine to aspartic acid substitution of either DAPK- or DAPK- in HeLa cells. As the results of kinase assays from both DAPK- and DAPK- mutants are indistinguishable, only the results for mouse DAPK- are shown in Fig. 3, A and B. As expected, both mutant forms of DAPK are not phosphorylated on Ser-308, as confirmed by the absence of signal using the phospho-Ser-308-DAPK-specific antibody (Fig. 3A). DAPK-S308D also has a lower affinity for Ca²⁺/CaM as evidenced by its inability to bind CaM in the presence of Ca²⁺ using a ligand-blotting assay (Fig. 3A). This result suggests that mutation of Ser-308 to aspartic acid (S308D) results in a kinase that resembles the Ser-308 autophosphorylated DAPK (Fig. 1B).

The kinase activities of these mutant mouse DAPKs were evaluated using an in vitro kinase assay with myosin II RLC as substrate (Fig. 3B). These assays showed that DAPK-S308A is twice as active as wild type DAPK (DAPK-WT), in the presence or absence of Ca²⁺/CaM, whereas DAPK-S308D retains less than 20% of the kinase activity of DAPK-WT. These data suggest that when expressed in cells, DAPK-S308D will act as a dominant negative by competing with endogenous DAPK.

Although mouse DAPK- and DAPK- have indistinguishable kinase activities, DAPK- is more potent than DAPK- in protecting HeLa cells from TNF-induced apoptosis (2). To test the effect of DAPK-Ser-308 mutants on TNF-induced apoptosis in HeLa cells, plasmids encoding either wild type or mutant DAPK- or DAPK- S308A or S308D were cotransfected with LacZ into HeLa cells. The transfection efficiency was similar for all the plasmids, as shown by Western blotting of recombinant DAPKs (Fig. 3C). After treatment with TNF/CHX for 4 h, cells were fixed and stained for LacZ expression. The percentage of LacZ-positive cells that had obvious apoptotic morphology (blebbing and condensed cytoplasm) was determined to monitor apoptosis (Fig. 3C). After 4 h of TNF treatment, 75% of control cells that were transfected with LacZ alone had apoptotic morphology. Cells that were transfected with mouse DAPK had a lower percentage of apoptotic cells, although statistical significance was achieved only for cells expressing DAPK-. Similarly, overexpression of DAPK--S308A, a mutant mouse DAPK- that has higher kinase activity than wild type DAPK- because of loss of the inactivating autophosphorylation site (Fig. 3B), further decreased the level of apoptotic cells to 30%. In contrast, overexpression of an autophosphorylation site mimetic, DAPK--S308D, a mutant DAPK- that has lower kinase activity than wild type DAPK- (Fig. 3B), increased the percentage of apoptotic cells to 90%, suggesting DAPK--S308D acts as a dominant negative to promote apoptosis. Consistent with our previous studies suggesting that overexpression of DAPK- does not overtly promote apoptosis, but rather acts as a weak survival factor (2), expression of either wild type, S308A, or S308D DAPK- form did not significantly increase or decrease the apoptotic levels of TNF-treated HeLa cells.

View larger version (29K): [in this window] [in a new window]   FIGURE 3. DAPK lacking an autophosphorylation site (S308A) has higher kinase activity and antagonizes apoptosis in HeLa cells treated with TNF or ceramide. A, Western blotting and calmodulin overlay of recombinant wild type (WT) or mutant (S308A or S308D) mouse DAPK- that was transiently overexpressed and immunoprecipitated from HeLa cells. The calmodulin overlay binding assay was performed using biotinylated CaM incubated with a Western blot of the immunoprecipitated DAPK. B, kinase assay of recombinant wild type or mutant (S308A or S308D) mouse DAPK- (MoDAPK) that was transiently overexpressed and immunoprecipitated from HeLa cells. Myosin II RLC was used as a substrate in the assay. The phosphorylated RLC (phospho-RLC) was detected using antibody specific for RLC phosphorylated at Ser-19. C, determination of TNF-induced apoptosis in HeLa cells cotransfected with recombinant wild type mouse DAPK- or DAPK- or their mutant forms (S308A or S308D) together with LacZ in a ratio of 5 to 1. At 24 h after transfection, cell extracts were analyzed by Western blotting to detect the Omni-tagged recombinant mouse DAPK. Transfected HeLa cells were treated with TNF (10 ng/ml) and CHX (10 µg/ml) for 4 h before being fixed and stained to detect LacZ-positive cells. Transfected, LacZ-positive cells were scored as either apoptotic or normal based on morphology after LacZ staining. Control cells were cotransfected with luciferase and LacZ. A minimum of 100 cells was counted for each analysis in three independent transfections. D, determination of caspase-3, caspase-8, and caspase-9 activities in HeLa cells cotransfected with recombinant wild type mouse DAPK- or DAPK- or their mutant forms (S308A or S308D) together with GFP in a ratio of 5 to 1. At 24 h after transfection, fluorescence-activated cell sorter-enriched GFP-positive cells were Western-blotted for recombinant DAPK. Enriched cells were treated with ceramide (50 µM) for 24 h; cell extracts were prepared, and then analyzed to quantify caspase activities using synthetic peptide substrates in a colorimetric assay. Results are from three separate caspase assays from three independent transfections.

View larger version (52K): [in this window] [in a new window]   FIGURE 4. Identification of an alternatively spliced human DAPK. A, Western blotting of human and mouse cell line whole cell lysates using an antibody that recognizes total DAPK (total DAPK) or an antibody raised against the 12 carboxyl-terminal residues (RDSHAWTPLYDL) that are unique for mouse DAPK- (2). B, reverse transcription PCR using primers designed to amplify the carboxyl terminus of both DAPK- and DAPK- detects both splice variants in human brain and HCASMC cDNAs. HASMC, primary human aortic smooth muscle cells; MC, primary mouse cardiomyocytes; Hu CASMC, primary human (Hu) coronary artery smooth muscle cells. C, schematic representation of the predicted DAPK- and DAPK- 3' alternative splicing (left) and protein structure (right). DAPK- uses an alternative splice site within the 3'-untranslated region of DAPK-, which results in deletion of 477 bp of the DAPK- and skips the DAPK- stop codon (-STOP). Use of this alternative splice site results in addition of 10 additional residues and utilizes the DAPK- stop codon (-STOP). Cloning and sequencing of the PCR products verified the DAPK- and DAPK- carboxyl-terminal sequences, shown below the protein schematic at the right side.

TNF Induces Proteasomal Degradation of DAPK—The results in Fig. 2 show that as the protein and activity levels of DAPK decrease after 60 min of TNF/CHX treatment, there is a corresponding increase in caspase-9 activity. We next determined whether the stability of the two DAPK isoforms is altered. With regard to this, we have previously identified a DAPK-interacting protein (DIP1/MIB1), which is an E3 ligase that can target DAPK for degradation by addition of poly-ubiquitin both in vitro and in vivo (17). To determine whether ubiquitination of DAPK is important for regulating its cellular levels in TNF-induced apoptosis and whether both forms of DAPK are equally sensitive to proteasome-mediated degradation, we compared the expression levels of recombinant mouse DAPK- and DAPK- in response to TNF/CHX or CHX alone (Fig. 5A). Western blotting to detect either the recombinant mouse DAPK- and DAPK- exogenously expressed in HeLa cells using an anti-Omni tag antibody shows that DAPK- is less stable than DAPK- (Fig. 5A), becoming undetectable after 7.5 h of TNF/CHX treatment, whereas the level for DAPK- is 25% of the initial level. In control experiments, using HeLa cells treated with CHX alone, the levels of both recombinant mouse DAPK- or DAPK- do not change, suggesting that the decline in expression is a specific response to TNF signaling (Fig. 5A).

To demonstrate that the endogenous human DAPK, similar to mouse DAPK, is also sensitive to ubiquitin-mediated degradation, we overexpressed the ubiquitin ligase that targets mouse DAPK, DIP1/MIB1 (Fig. 4B), and examined the effects on human DAPK stability using Western blotting. Treatment of the HeLa cells with TNF alone (no CHX) resulted in a significant reduction of the expression level of total human DAPK and DAPK- within 4 h (Fig. 5B) suggesting that TNF also results in human DAPK degradation. In HeLa cells overexpressing DIP1/MIB1, the relative levels of total human DAPK as well as the human DAPK- isoform are significantly lower than in respective parental HeLa cells either in the presence or absence of TNF. These results suggest that like mouse DAPK (2, 17), human DAPK can be targeted for degradation by DIP1/MIB1 and that ubiquitination of DAPK has a role in regulating the cellular levels of DAPK through proteasomal degradation.

To confirm that ubiquitination of DAPK was responsible for promoting the degradation of DAPK, we tested whether MG132, an inhibitor of proteasomal activity, could stabilize DAPK expression. Fig. 5C shows that the levels of the endogenous human total DAPK as well as DAPK- expression in TNF-treated HeLa cells are stabilized when the cells are treated with TNF/CHX and MG-132 (50 µM). To assess progression of TNF-induced apoptosis in this experiment, we also examined the cleavage of PARP into an 89-kDa fragment as an indicator of caspase activation (Fig. 5C). These results show that treatment of HeLa cells with MG-132 effectively inhibits PARP cleavage induced by TNF, a result consistent with the suggestion that an inverse relationship between caspase activity and DAPK expression levels exists in cells undergoing TNF-induced apoptosis.

View larger version (45K): [in this window] [in a new window]   FIGURE 5. DAPK is degraded by proteasomal activity during TNF-induced apoptosis. A, Western blotting of recombinant mouse DAPK- (MoDAPK-) and DAPK- (MoDAPK-) in HeLa cell lines treated with either TNF (10 ng/ml) and CHX (10 µg/ml) or CHX (10 µg/ml) alone for the indicated times. B, Western blotting of endogenous human DAPK- (HuDAPK) in HeLa cells or HeLa cells overexpressing the ubiquitin E3 ligase DIP-1 treated with TNF (10 ng/ml) or vehicle. Western blotting to detect vinculin was used to control for equal sample loading. C, Western blotting of endogenous human DAPK- in HeLa cells treated with TNF (10 ng/ml) and CHX (10 µg/ml) for indicated time, in the presence or absence of MG132 (50 µM), a proteasome inhibitor. Also shown is a Western blot of PARP, cleavage of which is used as an indicator of caspase activation.

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Our previous studies have shown that the cellular levels of DAPK can be directly regulated by proteasomal degradation and identified a novel DAPK E3 ubiquitin ligase containing three RING fingers called DIP1 (17). DIP1 was shown to mediate poly-ubiquitination of DAPK both in vitro and in vivo. Subsequently, DIP1 was shown to be identical to mindbomb (MIB1), and these experiments demonstrated that DIP1/MIB1 mono-ubiquitinates Delta-1 to cause its endocytosis as part of the initiation of the Notch signaling pathway (18). Although we cannot conclude that DIP1/MIB1 is the only ubiquitin ligase that has a direct role for regulating the cellular levels of DAPK, these studies have demonstrated that one mechanism for the attenuating DAPK activity is by its degradation via the proteasome. This conclusion is supported by the use of the proteasome inhibitor MG-132, which reverses degradation of human DAPK and in parallel abrogates TNF-induced apoptosis. These results indirectly link the cellular levels of DAPK to the rescue of HeLa cells from TNF-induced apoptosis.

It is not surprising that the temporal sequence of changes in DAPK autophosphorylation levels, catalytic activity, and expression levels in response to ceramide treatment parallels the changes observed for cells exposed to TNF. However, consistent with the known death-promoting effects of ceramide, the time course of these events is more protracted. Ceramide is a second messenger generated by TNF treatment, which also results in activation of non-caspase proteases like cathepsin B (28–30). Ceramides are also phosphatase activators (31–33), which may provide a link to the mechanism by which dephosphorylation of DAPK occurs. Although the exact phosphatase that dephosphorylates DAPK has not been characterized, a recent study found that FK506, a calcineurin inhibitor, can inhibit dephosphorylation of DAPK, raising the possibility that this phosphatase has a role in the activation of DAPK (34).

Although the role of DAPK in TNF signaling is not completely understood, it seems likely that DAPK has a unique and important role in this signaling cascade. In support of this proposal is the recent observation that DAPK associates with tumor necrosis factor receptor 1 and FADD in neuronal cells of rats stimulated to undergo seizure (35). This finding positions DAPK to have an important and direct role in TNF signaling. The TNF signaling pathway has two arms that can result in promoting apoptosis or alternatively promoting cell growth/proliferation. Our data suggest that activated DAPK may serve as a "checkpoint" or braking protein by opposing apoptosis. The initial increase in DAPK activity in response to TNF treatment could function as a cytoprotective mechanism that requires activation of DAPK to counter the apoptotic arm of the TNF signaling pathway. Thus, the early response to TNF stimulation is activation of DAPK, which functions to prevent cells from initiating apoptosis unless they are subjected to strong or prolonged stimulation. During a strong or prolonged apoptotic stimulus, the extent of degradation of DAPK varies depending on the rate of DAPK synthesis to alter the balance between survival and apoptosis.

Previous studies have identified two alternatively spliced isoforms of mouse DAPK (DAPK- and DAPK-) (2). These alternatively spliced forms of DAPK are identical in sequence except for 12 residues (RDSHAWTPLYDL) that extend the carboxyl terminus of DAPK-. Characterization of these two forms of mouse DAPK using overexpression and antisense depletion studies has shown that mouse DAPK- does not promote apoptosis and DAPK- attenuates TNF-induced apoptosis (7). This issue has called into question the relevance of studies utilizing the mouse DAPK isoforms and has led to the suggestion that mouse DAPK is functionally different from human DAPK (36). In this study, the existence of an alternatively spliced form of human DAPK has been confirmed using RT-PCR and Western blotting. Comparison of the carboxyl-terminal mouse and human sequences reveals considerable sequence identity, and thus it is unlikely that there is a functional difference between mouse and human DAPK. In support of this proposal, antisense depletion of DAPK from primary human smooth muscle cells results in spontaneous, caspase-dependent apoptosis (7).

In summary, this report focuses on extending previous studies, suggesting that inhibitory autophosphorylation at Ser-308 of DAPK is important for modifying the catalytic activity of DAPK (14), and we have examined the mechanism by which the activities of DAPK are modulated in response to apoptotic stimulation. The results presented here show that DAPK undergoes a transient activation, is subsequently ubiquitinated, and then degraded by the proteasome. This paradigm is analogous to those that have been identified for temporally regulating other apoptosis/proliferation regulatory proteins such as p53 and retinoblastoma and may be a common mechanism used to rapidly modulate the activities of these important homeostatic factors (37, 38). In addition to this mechanistic advance in our understanding of how the activities of DAPK are regulated, we have also confirmed the presence of an alternatively spliced human DAPK, denoted DAPK-. This finding suggests that the functional differences identified in previous studies using mouse DAPK (7) are not because of species variations between mouse and human DAPK.

	FOOTNOTES

 
^* This work was supported by National Institutes of Health Grant NHLBIHL54118 (to P. J. G.), American Heart Association Scientist Development Grant 0435064N (to Y. J.), and Indiana University Diabetes and Obesity Research Training Grant DK064466 (to E. K. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank^TM/EBI Data Bank with accession number(s) EF090258 [GenBank] .

¹ To whom correspondence should be addressed: Dept. of Cellular and Integrated Physiology, Indiana University School of Medicine, 635 Barnhill Dr., Indianapolis, IN 46202-5120; Tel.: 317-278-2146; Fax: 317-274-3318; E-mail: pgallag{at}iupui.edu.

² The abbreviations used are: DAPK, death-associated protein kinase; DIP1/MIB1, DAPK-interacting protein1/mindbomb1; TNF, tumor necrosis factor; CHX, cycloheximide; RLC, myosin II regulatory light chain; Ca²⁺/CaM, calcium/calmodulin; AP, alkaline phosphatase; PARP, poly(ADP-ribose) polymerase; Hu, human; pNA, p-nitroanilide; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; RT, reverse transcription; GFP, green fluorescent protein; E3, ubiquitin-protein isopeptide ligase.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Deiss, L. P., Feinstein, E., Berissi, H., Cohen, O., and Kimchi, A. (1995) Genes Dev. 9, 15–30[Abstract/Free Full Text]
2. Jin, Y., Blue, E. K., Dixon, S., Hou, L., Wysolmerski, R. B., and Gallagher, P. J. (2001) J. Biol. Chem. 276, 39667–39678[Abstract/Free Full Text]
3. Cohen, O., Inbal, B., Kissil, J. L., Raveh, T., Berissi, H., Spivak-Kroizaman, T., Feinstein, E., and Kimchi, A. (1999) J. Cell Biol. 146, 141–148[Abstract/Free Full Text]
4. Raveh, T., Droguett, G., Horwitz, M. S., DePinho, R. A., and Kimchi, A. (2001) Nat. Cell Biol. 3, 1–7[CrossRef][Medline] [Order article via Infotrieve]
5. Pelled, D., Raveh, T., Riebeling, C., Fridkin, M., Berissi, H., Futerman, A. H., and Kimchi, A. (2002) J. Biol. Chem. 277, 1957–1961[Abstract/Free Full Text]
6. Yamamoto, M., Hioki, T., Ishii, T., Nakajima-Iijima, S., and Uchino, S. (2002) Eur. J. Biochem. 269, 139–147[Medline] [Order article via Infotrieve]
7. Jin, Y., and Gallagher, P. J. (2003) J. Biol. Chem. 278, 51587–51593[Abstract/Free Full Text]
8. Chen, C. H., Wang, W. J., Kuo, J. C., Tsai, H. C., Lin, J. R., Chang, Z. F., and Chen, R. H. (2005) EMBO J. 24, 294–304[CrossRef][Medline] [Order article via Infotrieve]
9. Cohen, O., Feinstein, E., and Kimchi, A. (1997) EMBO J. 16, 998–1008[CrossRef][Medline] [Order article via Infotrieve]
10. Kishino, M., Yukawa, K., Hoshino, K., Kimura, A., Shirasawa, N., Otani, H., Tanaka, T., Owada-Makabe, K., Tsubota, Y., Maeda, M., Ichinose, M., Takeda, K., Akira, S., and Mune, M. (2004) J. Am. Soc. Nephrol. 15, 1826–1834[Abstract/Free Full Text]
11. Yukawa, K., Hoshino, K., Kishino, M., Mune, M., Shirasawa, N., Kimura, A., Tsubota, Y., Owada-Makabe, K., Tanaka, T., Ichinose, M., Maeda, M., Takeda, K., and Akira, S. (2004) Int. J. Mol. Med. 13, 515–520[Medline] [Order article via Infotrieve]
12. Yukawa, K., Hoshino, K., Kishino, M., Tsubota, Y., Owada-Makabe, K., Maeda, M., Bai, T., Tanaka, T., and Akira, S. (2005) Int. J. Mol. Med. 16, 389–393[Medline] [Order article via Infotrieve]
13. Yukawa, K., Kishino, M., Hoshino, K., Shirasawa, N., Kimura, A., Tsubota, Y., Owada-Makabe, K., Bai, T., Tanaka, T., Ueyama, T., Ichinose, M., Takeda, K., Akira, S., and Maeda, M. (2005) Int. J. Mol. Med. 15, 73–78[Medline] [Order article via Infotrieve]
14. Shohat, G., Spivak-Kroizman, T., Cohen, O., Bialik, S., Shani, G., Berrisi, H., Eisenstein, M., and Kimchi, A. (2001) J. Biol. Chem. 276, 47460–47467[Abstract/Free Full Text]
15. Kamm, K. E., and Stull, J. T. (2001) J. Biol. Chem. 276, 4527–4530[Free Full Text]
16. Zhi, G., Abdullah, S. M., and Stull, J. T. (1998) J. Biol. Chem. 273, 8951–8957[Abstract/Free Full Text]
17. Jin, Y., Blue, E. K., Dixon, S., Shao, Z., and Gallagher, P. J. (2002) J. Biol. Chem. 277, 46980–46986[Abstract/Free Full Text]
18. Itoh, M., Kim, C. H., Palardy, G., Oda, T., Jiang, Y. J., Maust, D., Yeo, S. Y., Lorick, K., Wright, G. J., Ariza-McNaughton, L., Weissman, A. M., Lewis, J., Chandrasekharappa, S. C., and Chitnis, A. B. (2003) Dev. Cell 4, 67–82[CrossRef][Medline] [Order article via Infotrieve]
19. Citri, A., Harari, D., Shohat, G., Ramakrishnan, P., Gan, J., Lavi, S., Eisenstein, M., Kimchi, A., Wallach, D., Pietrokovski, S., and Yarden, Y. (2006) J. Biol. Chem. 281, 14361–14369[Abstract/Free Full Text]
20. Bai, T., Tanaka, T., Yukawa, K., Maeda, M., and Umesaki, N. (2004) Oncol. Rep. 11, 661–665[Medline] [Order article via Infotrieve]
21. Friedrich, M. G., Weisenberger, D. J., Cheng, J. C., Chandrasoma, S., Siegmund, K. D., Gonzalgo, M. L., Toma, M. I., Huland, H., Yoo, C., Tsai, Y. C., Nichols, P. W., Bochner, B. H., Jones, P. A., and Liang, G. (2004) Clin. Cancer Res. 10, 7457–7465[Abstract/Free Full Text]
22. Kim, W. S., Son, H. J., Park, J. O., Song, S. Y., and Park, C. (2003) Int. J. Mol. Med. 12, 827–830[Medline] [Order article via Infotrieve]
23. Narayan, G., Arias-Pulido, H., Koul, S., Vargas, H., Zhang, F. F., Villella, J., Schneider, A., Terry, M. B., Mansukhani, M., and Murty, V. V. (2003) Mol. Cancer 2, 24[CrossRef][Medline] [Order article via Infotrieve]
24. Li, J., El-Naggar, A., and Mao, L. (2005) Cancer 104, 771–776[CrossRef][Medline] [Order article via Infotrieve]
25. Reddy, A. N., Jiang, W. W., Kim, M., Benoit, N., Taylor, R., Clinger, J., Sidransky, D., and Califano, J. A. (2003) Cancer Res. 63, 7694–7698[Abstract/Free Full Text]
26. Schildhaus, H. U., Krockel, I., Lippert, H., Malfertheiner, P., Roessner, A., and Schneider-Stock, R. (2005) Int. J. Oncol. 26, 1493–1500[Medline] [Order article via Infotrieve]
27. Tereshko, V., Teplova, M., Brunzelle, J., Watterson, D. M., and Egli, M. (2001) Nat. Struct. Biol. 8, 899–907[CrossRef][Medline] [Order article via Infotrieve]
28. Foghsgaard, L., Wissing, D., Mauch, D., Lademann, U., Bastholm, L., Boes, M., Elling, F., Leist, M., and Jaattela, M. (2001) J. Cell Biol. 153, 999–1010[Abstract/Free Full Text]
29. Foghsgaard, L., Lademann, U., Wissing, D., Poulsen, B., and Jaattela, M. (2002) J. Biol. Chem. 277, 39499–39506[Abstract/Free Full Text]
30. Guicciardi, M. E., Miyoshi, H., Bronk, S. F., and Gores, G. J. (2001) Am. J. Pathol. 159, 2045–2054[Abstract/Free Full Text]
31. Chalfant, C. E., Kishikawa, K., Mumby, M. C., Kamibayashi, C., Bielawska, A., and Hannun, Y. A. (1999) J. Biol. Chem. 274, 20313–20317[Abstract/Free Full Text]
32. Kishikawa, K., Chalfant, C. E., Perry, D. K., Bielawska, A., and Hannun, Y. A. (1999) J. Biol. Chem. 274, 21335–21341[Abstract/Free Full Text]
33. Chalfant, C. E., Szulc, Z., Roddy, P., Bielawska, A., and Hannun, Y. A. (2004) J. Lipid Res. 45, 496–506[Abstract/Free Full Text]
34. Shamloo, M., Soriano, L., Wieloch, T., Nikolich, K., Urfer, R., and Oksenberg, D. (2005) J. Biol. Chem. 280, 42290–42299[Abstract/Free Full Text]
35. Henshall, D. C., Araki, T., Schindler, C. K., Shinoda, S., Lan, J. Q., and Simon, R. P. (2003) J. Neurochem. 86, 1260–1270[Medline] [Order article via Infotrieve]
36. Bialik, S., and Kimchi, A. (2006) Annu. Rev. Biochem. 75, 189–210[CrossRef][Medline] [Order article via Infotrieve]
37. Shimizu, H., Saliba, D., Wallace, M., Finlan, L., Langridge-Smith, P. R., and Hupp, T. R. (2006) Biochem. J. 397, 355–367[CrossRef][Medline] [Order article via Infotrieve]
38. Ying, H., and Xiao, Z. X. (2006) Cell Cycle 5, 506–508[Medline] [Order article via Infotrieve]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. Stevens, Y. Lin, B. Harrison, L. Burch, R. A. Ridgway, O. Sansom, and T. Hupp Peptide Combinatorial Libraries Identify TSC2 as a Death-associated Protein Kinase (DAPK) Death Domain-binding Protein and Reveal a Stimulatory Role for DAPK in mTORC1 Signaling J. Biol. Chem., January 2, 2009; 284(1): 334 - 344. [Abstract] [Full Text] [PDF]

				Y.-T. Chuang, L.-W. Fang, M.-H. Lin-Feng, R.-H. Chen, and M.-Z. Lai The Tumor Suppressor Death-Associated Protein Kinase Targets to TCR-Stimulated NF-{kappa}B Activation J. Immunol., March 1, 2008; 180(5): 3238 - 3249. [Abstract] [Full Text] [PDF]

				L. Zhang, K. P. Nephew, and P. J. Gallagher Regulation of Death-associated Protein Kinase: STABILIZATION BY HSP90 HETEROCOMPLEXES J. Biol. Chem., April 20, 2007; 282(16): 11795 - 11804. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 281/51/39033    most recent M605097200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jin, Y. Articles by Gallagher, P. J. Search for Related Content PubMed PubMed Citation Articles by Jin, Y. Articles by Gallagher, P. J. Social Bookmarking                      What's this?